Skip to main content
. 2016 Jun 13;34(22):2619–2626. doi: 10.1200/JCO.2016.67.1529

Fig A4.

Fig A4.

Changes in subsets of T-cells according to confirmed best response. (A) Changes in activated CD8+ T-cell count after administration of talimogene laherparepvec and talimogene laherparepvec + ipilimumab. (B) Changes in ICOS+ CD4+ T-cell count after administration of talimogene laherparepvec and talimogene laherparepvec + ipilimumab. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.